This insight brief examines the rapid growth of alternative access channels for GLP-1 therapies, including telehealth providers, online pharmacies, and compounding pharmacies. It highlights how demand driven by obesity and diabetes management is reshaping traditional care pathways. The brief analyzes patient motivations such as convenience, affordability, and access constraints, as well as associated risks related to safety, continuity of care, and regulatory oversight. IQVIA outlines implications for manufacturers, payers, and providers, emphasizing the need for monitoring channel dynamics, patient education, and data-driven strategies to ensure appropriate access and outcomes.

Join for free to read